TY - JOUR
T1 - Phenotypic and genetic spectrum of epilepsy with myoclonic atonic seizures
AU - EuroEPINOMICS RES Consortium
AU - Tang, Shan
AU - Addis, Laura
AU - Smith, Anna
AU - Topp, Simon D.
AU - Pendziwiat, Manuela
AU - Mei, Davide
AU - Parker, Alasdair
AU - Agrawal, Shakti
AU - Hughes, Elaine
AU - Lascelles, Karine
AU - Williams, Ruth E.
AU - Fallon, Penny
AU - Robinson, Robert
AU - Cross, Helen J.
AU - Hedderly, Tammy
AU - Eltze, Christin
AU - Kerr, Tim
AU - Desurkar, Archana
AU - Hussain, Nahin
AU - Kinali, Maria
AU - Bagnasco, Irene
AU - Vassallo, Grace
AU - Whitehouse, William
AU - Goyal, Sushma
AU - Absoud, Michael
AU - Møller, Rikke S.
AU - Helbig, Ingo
AU - Weber, Yvonne G.
AU - Marini, Carla
AU - Simpson, Michael A.
AU - Guerrini, Renzo
AU - Pal, Deb K.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Objective: We aimed to describe the extent of neurodevelopmental impairments and identify the genetic etiologies in a large cohort of patients with epilepsy with myoclonic atonic seizures (MAE). Methods: We deeply phenotyped MAE patients for epilepsy features, intellectual disability, autism spectrum disorder, and attention-deficit/hyperactivity disorder using standardized neuropsychological instruments. We performed exome analysis (whole exome sequencing) filtered on epilepsy and neuropsychiatric gene sets to identify genetic etiologies. Results: We analyzed 101 patients with MAE (70% male). The median age of seizure onset was 34 months (range = 6-72 months). The main seizure types were myoclonic atonic or atonic in 100%, generalized tonic-clonic in 72%, myoclonic in 69%, absence in 60%, and tonic seizures in 19% of patients. We observed intellectual disability in 62% of patients, with extremely low adaptive behavioral scores in 69%. In addition, 24% exhibited symptoms of autism and 37% exhibited attention-deficit/hyperactivity symptoms. We discovered pathogenic variants in 12 (14%) of 85 patients, including five previously published patients. These were pathogenic genetic variants in SYNGAP1 (n = 3), KIAA2022 (n = 2), and SLC6A1 (n = 2), as well as KCNA2, SCN2A, STX1B, KCNB1, and MECP2 (n = 1 each). We also identified three new candidate genes, ASH1L, CHD4, and SMARCA2 in one patient each. Significance: MAE is associated with significant neurodevelopmental impairment. MAE is genetically heterogeneous, and we identified a pathogenic genetic etiology in 14% of this cohort by exome analysis. These findings suggest that MAE is a manifestation of several etiologies rather than a discrete syndromic entity.
AB - Objective: We aimed to describe the extent of neurodevelopmental impairments and identify the genetic etiologies in a large cohort of patients with epilepsy with myoclonic atonic seizures (MAE). Methods: We deeply phenotyped MAE patients for epilepsy features, intellectual disability, autism spectrum disorder, and attention-deficit/hyperactivity disorder using standardized neuropsychological instruments. We performed exome analysis (whole exome sequencing) filtered on epilepsy and neuropsychiatric gene sets to identify genetic etiologies. Results: We analyzed 101 patients with MAE (70% male). The median age of seizure onset was 34 months (range = 6-72 months). The main seizure types were myoclonic atonic or atonic in 100%, generalized tonic-clonic in 72%, myoclonic in 69%, absence in 60%, and tonic seizures in 19% of patients. We observed intellectual disability in 62% of patients, with extremely low adaptive behavioral scores in 69%. In addition, 24% exhibited symptoms of autism and 37% exhibited attention-deficit/hyperactivity symptoms. We discovered pathogenic variants in 12 (14%) of 85 patients, including five previously published patients. These were pathogenic genetic variants in SYNGAP1 (n = 3), KIAA2022 (n = 2), and SLC6A1 (n = 2), as well as KCNA2, SCN2A, STX1B, KCNB1, and MECP2 (n = 1 each). We also identified three new candidate genes, ASH1L, CHD4, and SMARCA2 in one patient each. Significance: MAE is associated with significant neurodevelopmental impairment. MAE is genetically heterogeneous, and we identified a pathogenic genetic etiology in 14% of this cohort by exome analysis. These findings suggest that MAE is a manifestation of several etiologies rather than a discrete syndromic entity.
KW - Doose syndrome
KW - epilepsy/seizures
KW - genetics
KW - myoclonic astatic epilepsy
UR - http://www.scopus.com/inward/record.url?scp=85085582268&partnerID=8YFLogxK
U2 - 10.1111/epi.16508
DO - 10.1111/epi.16508
M3 - Article
C2 - 32469098
AN - SCOPUS:85085582268
SN - 0013-9580
VL - 61
SP - 995
EP - 1007
JO - Epilepsia
JF - Epilepsia
IS - 5
ER -